Q-omics provides the consensus-scored PCED1A profile across patient tissues and cancer cell-line models. PCED1A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PCED1A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PCED1A RNA expression shows 18,465 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where PCED1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCED1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCED1A survival associations across molecular data types. PCED1A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCED1A RNA expression–survival associations across cancer types. High PCED1A expression shows unfavorable associations in COAD, KIRC, LIHC, LUAD and KICH, but favorable associations in PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for PCED1A RNA expression.
This table summarizes PCED1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCED1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCED1A shows higher tumor expression in KIRC, HNSC, COAD, STAD, LIHC and KIRP. The KIRC box plot shows higher PCED1A RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with PCED1A in patient tissues and cancer cell lines. In patient samples, PCED1A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCED1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
